Huntington’s Disease Care, Education, and Research Center: Clinical Trials

Huntington’s Disease Clinical Trials

Active, Currently Enrolling:

  • Enroll-HD: is a worldwide observational study for family members affected by Huntington’s disease, including spouses. Participants attend an annual study session at where they undergo a series of movement, behavioral and task-oriented tests, as well as a quality-of-life evaluation. Participants also may choose to donate a small volume of blood.​
  • HD Clarity: is an extension of the Enroll-HD study with a primary objective of collecting high quality CSF samples for evaluation of biomarkers and pathways that will enable the development of novel treatments for HD. This study involves a screening visit and sampling visit.
  • Kinect-HD 2: is a phase 3 open-label study to evaluate the long-term safety and tolerability of Valbenazine, and to provide subjects continued access to Valbenazine for the treatment of chorea associated with Huntington’s disease.

Active, Not Enrolling:

  • Annexon: is a multi-center, open-label study of intravenous ANX005 administered for up to 22 weeks in subjects with Huntington’s Disease or at risk for Huntington’s Disease. The purpose of this study is to find out if the investigational drug ANX005 is well tolerated and safe in subjects.
  • PROOF-HD: is a worldwide clinical trial studying pridopidine as a possible treatment for Huntington’s Disease. This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pridopidine 45 mg twice a day in patients with early stage HD. The study will last between 65-78 weeks and will have the option to enroll into an open-label extension.

Find more Clinical Trial information at MedStar Georgetown University Hospital.